Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction : DAPA-MI
Aims: In the randomized DAPA-MI clinical trial, 10 mg of dapagliflozin once daily improved cardiometabolic outcomes versus placebo after acute myocardial infarction (MI) in patients without established diabetes or heart failure (HF). We assessed associations between baseline left ventricular ejection fraction (LVEF) and cardiometabolic outcomes in DAPA-MI. Methods: The primary outcome, assessed us
